March 3, 2026Open Access

Vericiguat attenuates cyclosporine A-induced nephropathy by targeting the NF-κB/TGF-β1 axis: an integrated network pharmacology, Mendelian randomization, and experimental study

Key Points

Vericiguat shows significant renoprotective effects related to cyclosporine A-induced nephropathy.
In experiments, vericiguat effectively modulates the NF-κB/TGF-β1 axis, impacting inflammation and fibrosis.
This analysis includes experimental models and explores network pharmacology along with Mendelian randomization techniques.
Findings support potential drug repurposing for chronic kidney disease treatments, highlighting vericiguat's therapeutic implications.

Abstract

This study demonstrates that vericiguat exerts renoprotective, anti-inflammatory, and anti-fibrotic effects in CsA-induced CKD by modulating the NF-κB/TGF-β1 axis. These findings provide a novel scientific rationale for drug repurposing of vericiguat and highlight its potential therapeutic value for CKD.

Vericiguat attenuates cyclosporine A-induced nephropathy by targeting the NF-κB/TGF-β1 axis: an integrated network pharmacology, Mendelian randomization, and experimental study

Key Points

Abstract

Cite This Study